articleScience Translational MedicineJul 19, 2017GREEN OA

A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastoma

University of Pennsylvania · Novartis (United States) · +4 more institutions

Indexed incrossref

Abstract

A trial of autologous T cells redirected to a specific mutation in glioblastoma patients illustrates mechanisms of resistance.

No related works found for this paper.